![Jim Fenton](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jim Fenton
Investor Relations Contact at Association for Accessible Medicines
Jim Fenton active positions
Companies | Position | Start | End |
---|---|---|---|
Association for Accessible Medicines
![]() Association for Accessible Medicines Miscellaneous Commercial ServicesCommercial Services The Association for Accessible Medicines is an organization that aims to make generic and biosimilar medicines more accessible to those who need them. The organization is based in Arlington, VA. The non-profit company believes that increasing competition is the key to tackling the high cost of prescription drugs, rather than shifting costs among healthcare stakeholders. In 2022, generic and biosimilar prescription medicines saved $408 billion for the healthcare system overall, with more than $2.90 trillion saved over the past 10 years. The company was founded by Milan Puskar, Robert R. Grusky. David Gaugh has been the CEO of the company since 2012. | Investor Relations Contact | - | - |
Career history of Jim Fenton
Training of Jim Fenton
Georgetown University | Undergraduate Degree |
University of Oregon | Undergraduate Degree |
Statistics
International
United States | 4 |
Operational
Undergraduate Degree | 2 |
Investor Relations Contact | 1 |
Sectoral
Consumer Services | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Association for Accessible Medicines
![]() Association for Accessible Medicines Miscellaneous Commercial ServicesCommercial Services The Association for Accessible Medicines is an organization that aims to make generic and biosimilar medicines more accessible to those who need them. The organization is based in Arlington, VA. The non-profit company believes that increasing competition is the key to tackling the high cost of prescription drugs, rather than shifting costs among healthcare stakeholders. In 2022, generic and biosimilar prescription medicines saved $408 billion for the healthcare system overall, with more than $2.90 trillion saved over the past 10 years. The company was founded by Milan Puskar, Robert R. Grusky. David Gaugh has been the CEO of the company since 2012. | Commercial Services |
- Stock Market
- Insiders
- Jim Fenton
- Experience